Weill Cornell Medicine, a renowned biomedical research unit has recently announced that it has joined forces with the TriNetX global health research network. Reportedly, this move will enable Weill Cornell to collaborate with researchers and attract various clinical trial opportunities in the healthcare fraternity.
For the record, Weill Cornell is a unified academic healthcare delivery system, and now as a TriNetX global health research member, its entire patient population data of around two million will be accessible for query through TriNetX’s federated network. For those unfamiliar, TriNetX network includes healthcare organizations with approximately 100 million global patients, contract research organizations, and biopharmaceutical companies.
Amidst the backdrop of this move, industry experts speculate that several pharmaceutical companies are seen collaborating with their peer-companies and contract research organizations (CROs) to effectively manage operation expenses and overall healthcare costs. This Weill Cornell-TriNetX move, perpetually likely to impact clinical trials, outsourcing, and CROs, is certain to have a lasting impact on the end-use trends of pharmacovigilance market share, cite reliable analysts.
Thomas Campion, Asst Prof. of Healthcare Policy & Research and Director of Research Informatics at Weill Cornell Medicine, had been quoted stating that the unit is working to discover optimum approaches to support clinical research with e-patient data. Experts further cite that the move, with robust expansion in clinical research is likely to bring novel clinical trial opportunities in the pharmacovigilance industry.
Reports claim that as a part of TriNetX network, Weill Cornell will be able collaborate with more than 68 health organizations and will also be able to expand its existing i2b2 infrastructure to collaborate outside their institution. For the record, the de-identified data provided by Weill Cornell Medicine includes patient demographics, procedures, labs, medications, and diagnoses.
According to industry experts, the addition of new healthcare organizations to the TriNetX network enables several pharmaceutical companies to operationalize clinical trials, in turn allowing healthcare providers to present new therapies in global pharmacovigilance market.